ITOC 2022 | The major hurdles of CAR-T cell therapy for solid tumors

Florian Märkl, Ludwig-Maximilians-Universität München, Munich, Germany, provides an overview of the major hurdles associated with CAR-T cell therapy for solid tumors. This includes limited T-cell migration to the site of the tumor, the immunosuppressive tumor microenvironment (TME) and tumor heterogeneity. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.